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Cushing’s syndrome (CS) results from chronic levels of the 
hormone cortisol in the body either from endogenous or 
exogenous sources. Endogenous CS is a rare entity, with esti-
mated incidence of 2.4 cases per million populations per 
year.1 Traditionally, most of these cases are due to a pituitary 
adenoma (Cushing disease), which is thought to occur in 
80%–85% of cases. Small percentage of cases include adren-
ocorticotropic hormone (ACTH)-dependent CS (<10%) 
resulting from (non-pituitary) ectopic ACTH secretion (EAS) 
or, more rarely, corticotropin-releasing hormone by benign or 
malignant neoplasias such as a neuroendocrine tumour. The 
remaining percentage of patients (15%–20%) has ACTH-
independent CS, which is the result of either bilateral adreno-
cortical hyperplasia or adrenocortical tumours that secrete 
excessive cortisol, causing suppression of ACTH.2
The clinical manifestations are multiple. The typical com-
plaints of the patients are weight gain, especially in the face 
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Introduction: Data on specific abdominal surgery and Cushing’s syndrome are infrequent and are usually included in the 
adrenalectomy reports. Current literature suggests the feasibility and reproducibility of the surgical adrenalectomies for 
patients diagnosed with non-functioning tumours and functioning adrenal tumours including pheochromocytoma, Conn’s 
syndrome and Cushing’s syndrome.
Discussion: Medical treatment for Cushing’s syndrome is feasible but follow-up or clinical situations force the patient to 
undergo a surgical procedure. Laparoscopic surgery has become a gold standard nowadays in a broad spectrum of pathologies. 
Laparoscopic adrenalectomies are also standard procedures nowadays. However, despite the different characteristics and 
clinical disorders related to the laparoscopically removed adrenal tumours, the intraoperative and postoperative outcomes 
do not significantly differ in most cases between the different groups of patients, techniques and types of tumours. Tumour 
size, hormonal type and surgeon’s experience could be different factors that predict intraoperative and postoperative 
complications. Transabdominal and retroperitoneal approaches can be considered. Outcomes for Cushing’s syndrome do 
not differ depending on the surgical approach. Novel technologies and approaches such as single-port surgery or robotic 
surgery have proven to be safe and feasible.
Conclusion: Laparoscopic adrenalectomy is a safe and feasible approach to adrenal pathology, providing the patients with 
all the benefits of minimally invasive surgery. Single-port access and robotic surgery can be performed but more data are 
required to identify their correct role between the different surgical approaches. Factors such as surgeon’s experience, 
tumour size and optimal technique can affect the outcomes of this surgery.
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developing the classic ‘moon face’, supraclavicular fat pads, 
buffalo hump and central obesity. Other frequent signs are 
purple striae, acne, skin thinning, easy bruising, osteopenia, 
proximal muscle weakness, emotional liability, menstrual 
dysfunction, virilization in women and infertility2 (Figure 1). 
CS shortens the expectancy of life of the patients due to car-
diovascular disease, diabetes as well as hypertension (caused 
by cortisol, excess of sodium and water retention).1,2
As for the diagnosis, a detailed clinical history, physical 
examination, laboratory tests and radiologic evaluation 
can confirm the existence of a CS as well as determine its 
cause.
Medical treatment is based on the administration of adrenal 
enzyme inhibitors, such as ketoconazole, metyrapone, mito-
tane or aminogluthetimide.3 However, the blockage achieved is 
only transient and leads to significant potential liver toxicity. 
Many of these patients, however, will benefit from a surgical 
procedure. When considering surgery for CS, which results 
from an ACTH-producing tumour of the pituitary gland 
(Cushing’s disease), treatment may include medical inhibitors 
of the ACTH secretion, but also surgical removal of a small, 
well-defined pituitary adenoma.3 The transsphenoidal adenom-
ectomy surgical approach is the gold standard for the removal 
of these tumours.4 The access to this area through the gums 
above the upper front teeth or the nose is feasible with mini-
mally invasive surgery.5 By using special instruments, the sur-
geon makes an incision which is extended through the sphenoid 
sinus. Thus, the endoscopic view facilitates to remove the ade-
noma. This type of surgery and surgical approach permanently 
cures CS in 60%–70% of patients.6 In those cases where the 
tumour cannot be identified, hemihypophysectomy may be 
considered or even subtotal hypophysectomy.7 For some other 
patients, for whom the previous treatments have not been suc-
cessful, surgical removal of the adrenal glands should be rec-
ommended, including total excision of one or both adrenal 
glands. Also, patients diagnosed with non-functioning adrenal 
tumour (NFT) and functioning adrenal tumour (FT) including 
pheochromocytoma (PH), Conn’s syndrome (CO) and CS 
might benefit from a surgical approach. For patients with corti-
cotropin (ACTH)-dependent CS who have experienced failed 
attempts to remove the pituitary or ectopic neoplasm, bilateral 
adrenalectomy emerges as an excellent treatment option, 
resulting in immediate cure of hypercortisolism-related symp-
toms even in those patients with disseminated, untreatable 
malignancy.3,8
Surgical management and factors 
related
It is generally accepted that the laparoscopic approach (LA) 
offers some advantages compared with the open approach 
(OA) such as shorter postoperative recovery time, less long-
term morbidity, earlier return to daily activities, early return of 
bowel function and low rate of wound infection and hernia.2,3,9 
Some authors have tried to define which should be the criteria 
to perform LA versus OA. Factors such as suspicious of 
malignancy, a large size of the tumour, morbid obesity and 
invasion of the surrounding structures have been described as 
some reasons for conversion to open surgery without a doubt.10
In a survey conducted by the endocrine surgery section of 
Spanish Association of Surgeons,11 it was found that the LA 
was generally the procedure chosen by 84% of the surgeons 
who responded to the survey. According to their results, they 
had a lower rate for conversion to laparotomy (6.7%), over-
all morbidity (8.9%), urgent re-operation (2.3%) and mortal-
ity (0.3%) as well as a length of hospital stay of 4.9 days. In 
addition, it was shown that laparoscopic adrenal surgery was 
usually performed by a small number of surgeons in endo-
crine surgery units in large hospitals. Various US and 
European articles have analysed the influence of the volume 
of activity on the patients’ outcome. The outcome of these 
procedures does not appear to depend generally on the type 
of hormonal secretion by the adrenal lesion. Laparoscopy 
offers the possibility to operate tumours responsible for inci-
dentalomas, CO, CS or even PH.12–15
The surgeon should choose the type of procedure after a 
thorough preoperative study.16 Once the approach is chosen, 
which in most of the cases will be laparoscopically, adrenal-
ectomies can be performed safely.11
LA to the adrenal gland
There are many ways to approach the adrenal gland laparo-
scopically, such as by a lateral transperitoneal approach, 
anterior transperitoneal approach, lateral retroperitoneal 
approach and posterior transperitoneal approach. A clear 
evolution has been observed during the past 20 years in the 
endocrinologic surgical field, especially when dealing with 
new approaches and technologies.
Figure 1. Patient who underwent laparoscopic adrenalectomy 
presenting weight gain, supraclavicular fat pads, buffalo hump and 
central obesity. We can observe the classical purple striae with 
acne.
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The standard LA was first reported in 1992 by Gagner 
et al.,17 and nowadays, it is defined as the standard of care for 
adrenal pathology.3 Even when there is suspicious of malig-
nancy or adrenal masses >7 cm, LA is considered a safe option.9 
When compared to medical therapy, laparoscopic adrenalec-
tomy is superior in terms of tolerance, efficacy and safety.3 The 
choice of approach in laparoscopic adrenalectomy is dependent 
upon surgeon because there have not been found any superiority 
in either the transperitoneal or the retroperitoneal approach. 
Some surgeons do prefer the retroperitoneal approach for 
patients who have had prior abdominal surgery.3 In addition, the 
benefits of this approach are said to be a shorter operating time, 
reduced blood loss and reduced risk of injury to the viscera. The 
retroperitoneal approach uses the retroperitoneal space in order 
to access the gland. A bilateral adrenalectomy can be performed 
in this fashion by experienced surgeons with the patient in prone 
position without having to move the patient.9 Nevertheless, the 
lateral transperitoneal approach is preferred by most of the sur-
geons because the working space is wider, the anatomic land-
marks are clearer and the fact that lateral decubitus and the 
medial rotation of the viscera allow gravity to keep the viscera 
away from the surgical field. The transperitoneal route is a more 
standardised approach where the adrenal gland is reached by 
entering the abdominal cavity (Figure 2).
The laparoscopic technique pretends to remove the gland 
by previously identifying, clipping and dividing the adrenal 
vein (right or left). Each adrenalectomy performed on each 
side has specific anatomical landmarks that skilled endo-
crine surgeon has to respect in order to perform a standard 
adrenalectomy.11
Factors related to laparoscopic 
outcomes
In a personal review, limiting the search for reviews and sys-
tematic reviews with the keywords ‘adrenalectomy, surgery 
and Cushing syndrome’, 154 articles were included in the 
final study after performing the first search. All abstracts 
were reviewed and 33 articles were selected according to the 
information provided with reference to CS. All these studies 
suggest the feasibility and reproducibility of the adrenalecto-
mies. Many of the articles showed results with patients diag-
nosed with NFT, FT, PH, CO syndrome and CS. However, 
despite the different characteristics and clinical disorders 
related to laparoscopically removed adrenal tumours, the 
intraoperative and postoperative outcomes did not signifi-
cantly differ in most cases between the different groups of 
patients, techniques and types of tumours. Tumour size, hor-
monal type and surgeon’s experience could be different fac-
tors that predict intraoperative and postoperative 
complications. CS does not differ in terms of surgical 
approach compared to other types of adrenal tumours. LA for 
CS is highly successful for pituitary-dependent CS and most 
ACTH-independent adrenal causes.
Size could be an issue in non-functional tumours, where a 
size of an adrenal tumour (>8 cm) and/or the evidence of its 
local invasiveness (both primary and metastatic adrenal 
malignancy) are still considered in many centres to be con-
traindications to a LA.12,13,15–19
Many authors have suggested that outcomes after laparo-
scopic procedure are related to endocrine tumour secretion, 
size of the tumour and the patient’s age.15,20 We believe that 
in the case of larger tumours, the transabdominal approach 
should be used in order to have an early closure of the adre-
nal vein avoiding, for example, the life-threatening output of 
catecholamine.20,21 The commonest complication reported is 
the tissue bleeding.22 This complication can usually be con-
trolled surgically during LA, but conversion to open surgery 
can be necessary because the ongoing tissue bleeding could 
not allow a safe tumour dissection. Severe bleedings can 
occur when dealing with the inferior cava vein during 
removal of a right adrenal lesion. The lesion of the perito-
neum can be a problem when undergoing extraperitoneal 
LA. An anterior approach can then be required. Surgeon’s 
experience with advanced laparoscopic procedures is related 
to outcomes, and they are comparable to the outcome of LA 
performed for all tumours with hormonal disorders.21,23–26 
Thus, a lower rate of postoperative complications and hospi-
tal stay after adrenalectomy is found when it is performed by 
a surgeon and in a hospital with a high volume of surgical 
activity.11 Laparoscopic adrenalectomy is currently used to 
treat patients for whom malignancy is not suspected, while 
open surgery is still considered the standard treatment 
approach in patients with suspect of malignancy.27
Conversion from LA to OA ranges between 0% and 
13%.14 Bleeding is the main cause for conversion and other 
causes include the following: difficult dissection or detec-
tion of the adrenal tumour, opening of the peritoneum when 
performing extraperitoneal approach and the presence of a 
pneumothorax. Gumbs and Gagner did not found differ-
ences related to the hormonal type of tumour,14 although 
Figure 2. Patient’s positioning before performing a left robotic 
transabdominal laparoscopic adrenalectomy in a patient with CS.
CS: Cushing’s syndrome.
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the surgeon’s experience, the size of the tumour and the 
body mass index could be predictive for conversion to 
OA.21,24–27 The keys to successful laparoscopic adrenalec-
tomy should be an appropriate patient selection, a clear 
knowledge of the anatomy, delicate tissue handling, metic-
ulous haemostasis and experience with the technique of 
laparoscopic adrenalectomy.28 Finally, patients undergoing 
surgery with CS have a higher predisposition to develop 
complications related to cicatrisation, coagulation and also 
related to infections.29
New surgical technologies
Clearly, recent advances in imaging, along with develop-
ments in neurosurgery with the transsphenoidal approach 
and also the laparoscopic surgery, have had the greatest 
impact on today’s management of the complex patient with 
CS. All these advances include the use of new devices and 
approaches. New surgical approaches such as robotic or sin-
gle-port access (SPA) surgery have been used in many other 
procedures such as appendectomy, cholecystectomy or even 
bariatric procedures.29–31 Adrenalectomy has also been one 
of the indications in which single access can be used.32–34 
Last but not least, the robotic approach in selected patients 
with ACTH-dependent CS, such as patients with persistent 
Cushing’s disease after failed hypophysectomy or patients 
with ectopic ACTH production that may require bilateral 
adrenalectomy, could be used.35 
Robotic adrenal surgery
As mentioned before, a new special tool for adrenal sur-
gery came from a continuous development of new devices, 
and technologies such as robotic systems (da Vinci®) and 
single-port robotic incision/access devices have lead to 
better postoperative pain control, better cosmetic result, 
decreased length of stay and same postoperative results.36 
Robotic surgery has proven to assess the surgical anatomy 
of the adrenal glands, its vascularisation and the surround-
ing structures, through a high-definition and magnified 
three-dimensional view of the operating field provided by 
the da Vinci surgical system (Intuitive Surgical, Sunnyvale, 
CA, USA) (Figures 2 and 3). This technique performed 
under the da Vinci Surgical system can be safer and can 
offer the promise of a unique combination of advantages 
over open and conventional LAs. However, there is still a 
lack of clinical data demonstrating improved outcomes for 
robotic surgical applications within the abdomen and also 
for adrenalectomy.37–39 Thus, more outcome data for surgi-
cal robotics should be given in order to elucidate the real 
benefit compared to the exorbitant costs associated with 
the use of these tools. The performance of unilateral or 
synchronous bilateral adrenalectomy treated using the da 
Vinci robot (Intuitive Surgical) has been described.38 
Although, some studies have mentioned that laparoscopic 
adrenalectomy is superior to robot-assisted adrenalectomy 
in terms of feasibility, morbidity and cost.40–42 We can con-
clude, and according to some of the reviewed papers, that 
bilateral total adrenalectomy can also provide effective 
palliation from hypercortisolism in patients with ectopic 
ACTH syndrome and for those who have failed previous 
transsphenoidal surgery.43 The da Vinci technology can 
nowadays be applied through a single incision.44
Single-site access adrenal surgery
Recently, advanced laparoscopic skills accumulated from 
experience and new developments in laparoscopic instru-
ments have led to the introduction of SPA laparoscopic adre-
nalectomy.43 Many authors have already reported their 
previous experience in SPA, with good results. This SPA 
technique could provide potential benefits (lesser wound 
pain, better cosmetic satisfaction and shorter convales-
cence).45,46 Left adrenalectomy is a technically feasible and 
safe procedure in carefully selected patients. The definitive 
clinical, aesthetic and functional advantages of this tech-
nique require further analysis. The approach can be chal-
lenging for bilateral lesions. Although, further studies will be 
required in order to define and decide the patients who are 
more eligible for this approach.36 A summary of the different 
approaches is shown in Table 1.
Figure 3. External view of a robotic transabdominal 
laparoscopic adrenalectomy in a patient with CS.
CS: Cushing’s syndrome.
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For all these above-mentioned reasons, during the past 
decades, surgery has become the treatment of choice for 
patients with endogenous CS. Adrenalectomy, in particu-
lar, is a surgical procedure performed with increasing fre-
quency since 1980s, and over the last two decades, LA has 
become the surgical procedure of choice in the treatment 
of most benign adrenal lesions. Also, this approach is suit-
able for removal of both functional and non-functional 
tumours. Since then, as we have already mentioned, many 
authors have reported their experience with their results in 
OA and LA.
Conclusion
Laparoscopic adrenalectomy is nowadays the technique gold 
standard for the surgical management of CS because it allows 
the removal of adrenal lesions or bilateral adrenalectomy in 
the same act without an increase in morbidity. Moreover, 
surgery provides an immediate disease control. There are 
several studies that have shown its advantages compared 
with the OA such as reduced hospital stay, less postoperative 
pain and a decrease in transfusion requirements or wound 
morbidity. There are wide ranges of technical approaches, 
which are equally effective. As long as the surgeon has taken 
into account preoperatively key facts such as the size of the 
adrenal mass, the history of previous abdominal surgeries. 
Factors such as tumour size and surgeon’s experience may 
influence the surgical outcomes. New technologies such as 
robotic surgery or single-port surgery can offer new vistas 
for the future of adrenal surgery.
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Table 1. Table showing the different laparoscopic approaches with their usual accesses, number of trocars, advantages and 
disadvantages.
Transperitoneal Retroperitoneal Single-port access Robotic da Vinci® 
system
Access Trocars are placed through the 
anterior abdominal wall
Balloon dilatation of 
the retroperitoneum 
below the 12th rib
1 trocar placed umbilical Anterior or posterior
Number of 
trocars
Right: 4 (10 mm); left: 3 Right and left: 3 (5 
mm)
1 (24 mm) multiport Same as anterior or 




Previous surgical history (above all, 
kidney or liver procedures)
BMI > 45 Previous surgical history 
(above all, kidney or 
liver procedures)
Previous surgical history 
(above all, kidney or 
liver procedures)
Large gland (from 8 to 10 cm) Large gland Large gland (from 8 to 
10 cm)
Large gland (from 8 to 
10 cm)
Carcinoma Need to explore the 
rest of the abdomen 
(i.e. metastases)
BMI?
Advantages Minimally invasive Direct access to the 
gland
Less pain 3D vision
Magnified view Avoid the risk of 
viscera injury
Control of the vascular pedicles 
(obese patients)
No paralytic ileus Precision





Reduced hospital stay Ergonomics
Reduced wound morbidity
Pitfalls Liver, splenic and pancreatic injury Colonic injury Same as transperitoneal, 
including challenges for 
surgeon
Same as transabdominal 
approachTear of an accessory adrenal vein
Injury of the vena cava or the 
diaphragm
Division of a polar renal artery
Rupture of the capsule of the gland
BMI: body mass index (Kg/m2); 3D: three-dimensional.
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